Olanzapine for primary negative symptoms.
Licht
R W
RW
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012107:Research Design / Q000592:standards; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D006220:Haloperidol; D000077152:Olanzapine